Autologous umbilical cord blood infusion for the treatment of autism in young children: A within-subjects open label study on safety (assessed via caregiver report) and efficacy.
Cord blood infusion is safe for preschoolers with autism but offers little measurable benefit.
01Research in Context
What this study did
Doctors gave the preschoolers with autism a single infusion of their own stored cord blood.
Parents kept daily logs for six months to watch for side effects.
The team also tracked language, play, and social skills with standard tests.
What they found
No child had serious side effects.
About one-third of parents saw small gains in daily living skills.
Yet the formal tests showed no real change in language or IQ scores.
How this fits with other research
Murata et al. (2017) also used a before-and-after design. They found big drops in behavior problems after a simple tonsil surgery.
The cord blood study shows weaker effects than that surgery.
Byiers et al. (2025) reviewed Dutch autism care and listed cord blood as an "emerging alternative." Their map now includes this new safety data.
Boswell et al. (2023) looked at gut chemicals linked to anxiety. Like the cord blood team, they found biology changes that do not yet translate to clear ABA gains.
Why it matters
Cord blood is safe but not a game-changer. Keep using proven ABA tools. If parents ask about cord blood, you can say the risks look low but the payoff is small and uncertain.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →When a parent mentions cord blood, share this safety data and pivot back to evidence-based ABA goals.
02At a glance
03Original abstract
This study aimed to document the safety and efficacy of a single infusion of autologous umbilical cord blood (UCB) in 20 autistic children aged 24-72 months. A pre-post treatment within-subjects open label design was used. At T = 0, 6, 12, and 18 months, participants underwent detailed and structured safety evaluations (via caregiver report), Vineland Adaptive Behavior Scale (Vineland-3), Stanford Binet Intelligence Scale (SB-5), Expressive One-Word Picture Vocabulary Test, Brief Observation of Social Communication Change (BOSCC), Pervasive Developmental Disorder-Behavior Inventory, Repetitive Behavior Scale-Revised, Sensory Experience Questionnaire (SEQ-2.1), Child Behavior Checklist, Clinical Global Impression-Severity and Improvement (CGI-I) Scales, and eye-gaze tracking. UCB infusion was conducted at T = 6 months, hence, 0-6 months was the control period, and 6-18 months the follow-up period. Of 20 children recruited, 19 completed the study and 1 was withdrawn due to UCB not meeting quality control criteria for infusion. There were 15 males and 4 females with an overall mean (SD) age of 4.15 (0.62) years. Mean (SD) cell dose administered was 38.16 (9.82) million cells/kg. None suffered serious adverse events although there were mild behavioral side effects and one unit grew coagulase negative staphylococcus from a post-thaw sample. There were no significant differences in Vineland-3, SB-5, BOSCC, and SEQ-2.1 scores at T = 12 and T = 18 months. Twelve participants had T = 18 CGI-I scores of 2-3 (minimally to much improved), seven participants had scores of 4 (no change). Autologous UCB infusion in autistic children is generally safe but not without risks, including that of infection. In this within-subjects study, some children showed global symptom improvements while others showed no change. Stem cell therapies for autism should only be conducted under strict clinical trial conditions with clear risk discussions.
Autism research : official journal of the International Society for Autism Research, 2024 · doi:10.1002/aur.3187